
Abrocitinib is an oral, small molecule, Janus kinase (JAK) 1 inhibitor in development for the treatment of adults and adolescents with moderate to severe atopic dermatitis.
The global market for Abrocitinib API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Abrocitinib API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Abrocitinib API by region & country, by Type, and by Application.
The Abrocitinib API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Abrocitinib API.
Market Segmentation
By Company
Toronto Research Chemicals
Abcam
TargetMol Chemicals
Pfizer
Cayman Chemical
Clearsynth
Changzhou Pharmaceutical Factory
ComWin Internationa
Segment by Type:
Purity ≥ 98 %
Purity ≥ 99 %
Segment by Application
Research Institute
Pharmaceutical
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Abrocitinib API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Abrocitinib API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Abrocitinib API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Abrocitinib API Product Introduction
1.2 Global Abrocitinib API Market Size Forecast
1.2.1 Global Abrocitinib API Sales Value (2019-2030)
1.2.2 Global Abrocitinib API Sales Volume (2019-2030)
1.2.3 Global Abrocitinib API Sales Price (2019-2030)
1.3 Abrocitinib API Market Trends & Drivers
1.3.1 Abrocitinib API Industry Trends
1.3.2 Abrocitinib API Market Drivers & Opportunity
1.3.3 Abrocitinib API Market Challenges
1.3.4 Abrocitinib API Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Abrocitinib API Players Revenue Ranking (2023)
2.2 Global Abrocitinib API Revenue by Company (2019-2024)
2.3 Global Abrocitinib API Players Sales Volume Ranking (2023)
2.4 Global Abrocitinib API Sales Volume by Company Players (2019-2024)
2.5 Global Abrocitinib API Average Price by Company (2019-2024)
2.6 Key Manufacturers Abrocitinib API Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Abrocitinib API Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Abrocitinib API
2.9 Abrocitinib API Market Competitive Analysis
2.9.1 Abrocitinib API Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Abrocitinib API Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Abrocitinib API as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Purity ≥ 98 %
3.1.2 Purity ≥ 99 %
3.2 Global Abrocitinib API Sales Value by Type
3.2.1 Global Abrocitinib API Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Abrocitinib API Sales Value, by Type (2019-2030)
3.2.3 Global Abrocitinib API Sales Value, by Type (%) (2019-2030)
3.3 Global Abrocitinib API Sales Volume by Type
3.3.1 Global Abrocitinib API Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Abrocitinib API Sales Volume, by Type (2019-2030)
3.3.3 Global Abrocitinib API Sales Volume, by Type (%) (2019-2030)
3.4 Global Abrocitinib API Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Research Institute
4.1.2 Pharmaceutical
4.1.3 Others
4.2 Global Abrocitinib API Sales Value by Application
4.2.1 Global Abrocitinib API Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Abrocitinib API Sales Value, by Application (2019-2030)
4.2.3 Global Abrocitinib API Sales Value, by Application (%) (2019-2030)
4.3 Global Abrocitinib API Sales Volume by Application
4.3.1 Global Abrocitinib API Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Abrocitinib API Sales Volume, by Application (2019-2030)
4.3.3 Global Abrocitinib API Sales Volume, by Application (%) (2019-2030)
4.4 Global Abrocitinib API Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Abrocitinib API Sales Value by Region
5.1.1 Global Abrocitinib API Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Abrocitinib API Sales Value by Region (2019-2024)
5.1.3 Global Abrocitinib API Sales Value by Region (2025-2030)
5.1.4 Global Abrocitinib API Sales Value by Region (%), (2019-2030)
5.2 Global Abrocitinib API Sales Volume by Region
5.2.1 Global Abrocitinib API Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Abrocitinib API Sales Volume by Region (2019-2024)
5.2.3 Global Abrocitinib API Sales Volume by Region (2025-2030)
5.2.4 Global Abrocitinib API Sales Volume by Region (%), (2019-2030)
5.3 Global Abrocitinib API Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Abrocitinib API Sales Value, 2019-2030
5.4.2 North America Abrocitinib API Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Abrocitinib API Sales Value, 2019-2030
5.5.2 Europe Abrocitinib API Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Abrocitinib API Sales Value, 2019-2030
5.6.2 Asia Pacific Abrocitinib API Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Abrocitinib API Sales Value, 2019-2030
5.7.2 South America Abrocitinib API Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Abrocitinib API Sales Value, 2019-2030
5.8.2 Middle East & Africa Abrocitinib API Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Abrocitinib API Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Abrocitinib API Sales Value
6.2.1 Key Countries/Regions Abrocitinib API Sales Value, 2019-2030
6.2.2 Key Countries/Regions Abrocitinib API Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Abrocitinib API Sales Value, 2019-2030
6.3.2 United States Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Abrocitinib API Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Abrocitinib API Sales Value, 2019-2030
6.4.2 Europe Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Abrocitinib API Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Abrocitinib API Sales Value, 2019-2030
6.5.2 China Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.5.3 China Abrocitinib API Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Abrocitinib API Sales Value, 2019-2030
6.6.2 Japan Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Abrocitinib API Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Abrocitinib API Sales Value, 2019-2030
6.7.2 South Korea Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Abrocitinib API Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Abrocitinib API Sales Value, 2019-2030
6.8.2 Southeast Asia Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Abrocitinib API Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Abrocitinib API Sales Value, 2019-2030
6.9.2 India Abrocitinib API Sales Value by Type (%), 2023 VS 2030
6.9.3 India Abrocitinib API Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Toronto Research Chemicals
7.1.1 Toronto Research Chemicals Company Information
7.1.2 Toronto Research Chemicals Introduction and Business Overview
7.1.3 Toronto Research Chemicals Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Toronto Research Chemicals Abrocitinib API Product Offerings
7.1.5 Toronto Research Chemicals Recent Development
7.2 Abcam
7.2.1 Abcam Company Information
7.2.2 Abcam Introduction and Business Overview
7.2.3 Abcam Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Abcam Abrocitinib API Product Offerings
7.2.5 Abcam Recent Development
7.3 TargetMol Chemicals
7.3.1 TargetMol Chemicals Company Information
7.3.2 TargetMol Chemicals Introduction and Business Overview
7.3.3 TargetMol Chemicals Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.3.4 TargetMol Chemicals Abrocitinib API Product Offerings
7.3.5 TargetMol Chemicals Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Abrocitinib API Product Offerings
7.4.5 Pfizer Recent Development
7.5 Cayman Chemical
7.5.1 Cayman Chemical Company Information
7.5.2 Cayman Chemical Introduction and Business Overview
7.5.3 Cayman Chemical Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Cayman Chemical Abrocitinib API Product Offerings
7.5.5 Cayman Chemical Recent Development
7.6 Clearsynth
7.6.1 Clearsynth Company Information
7.6.2 Clearsynth Introduction and Business Overview
7.6.3 Clearsynth Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Clearsynth Abrocitinib API Product Offerings
7.6.5 Clearsynth Recent Development
7.7 Changzhou Pharmaceutical Factory
7.7.1 Changzhou Pharmaceutical Factory Company Information
7.7.2 Changzhou Pharmaceutical Factory Introduction and Business Overview
7.7.3 Changzhou Pharmaceutical Factory Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Changzhou Pharmaceutical Factory Abrocitinib API Product Offerings
7.7.5 Changzhou Pharmaceutical Factory Recent Development
7.8 ComWin Internationa
7.8.1 ComWin Internationa Company Information
7.8.2 ComWin Internationa Introduction and Business Overview
7.8.3 ComWin Internationa Abrocitinib API Sales, Revenue and Gross Margin (2019-2024)
7.8.4 ComWin Internationa Abrocitinib API Product Offerings
7.8.5 ComWin Internationa Recent Development
8 Industry Chain Analysis
8.1 Abrocitinib API Industrial Chain
8.2 Abrocitinib API Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Abrocitinib API Sales Model
8.5.2 Sales Channel
8.5.3 Abrocitinib API Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Toronto Research Chemicals
Abcam
TargetMol Chemicals
Pfizer
Cayman Chemical
Clearsynth
Changzhou Pharmaceutical Factory
ComWin Internationa
Ìý
Ìý
*If Applicable.
